184. ESMO Awards - Episode 4
from Oncology for the Inquisitive Mind
This week, we discuss neuroendocrine tumours and melanoma as our ESMO 25 journey continues. Trials for neuroendocrine cancers include HIF-2 alpha inhibitors, targeted alpha therapy, and a classic anti-PD-1/TIGIT bispecific antibody combined with standard etoposide and cisplatin chemotherapies. Melanoma is once again seeking that elusive breakthrough: the second-line therapy that demonstrates immunotherapy is not a one-time opportunity. We also highlight both the BNT111 RNA-based lipoplex immunotherapy targeting agent and the question of whether early discontinuation of immunotherapy could be beneficial. Studies: LITESPARK-15 IMPRESS-Norway trial Abstract 1510M0 BNT111 (NCT04526899) Safe Stop Trial For more episodes, resources and blog posts, visit www.inquisitiveonc.com Please find us on Twitter @InquisitiveOnc! If you want us to look at a specific trial or subject, email us at [email protected] Art courtesy of Taryn Silver Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/ Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice. Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. MSD provided virtual participation with ESMO. Our partners have access to the episode at the same time you do and have no editorial control over the content.
Embed this episode
No transcript yet.